Mega Lifesciences Dirección

Dirección controles de criterios 2/4

El CEO de Mega Lifesciences es Vivek Dhawan, nombrado en Jan 1988, tiene una permanencia de 36.83 años. posee directamente un 6.59% de las acciones de la empresa, con un valor de THB2.04B. La antigüedad media del equipo directivo y de la junta directiva es de 26.8 años y 11.8 años, respectivamente.

Información clave

Vivek Dhawan

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	36.8yrs
Participación del CEO	6.6%
Permanencia media de la dirección	26.8yrs
Promedio de permanencia en la Junta Directiva	11.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Vivek Dhawan (63 yo)

36.8yrs

Permanencia

Mr. Vivek Dhawan is CEO, Chief Coach & Executive Director of Mega Lifesciences Public Company Limited from 2013. He joined the Mega Lifesciences Public Company Limited in 1986. He is CEO & Chief Coach of M...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Vivek Dhawan	CEO, Chief Coach & Executive Director	36.8yrs	sin datos	6.59% THB 2.0b
Thomas Abraham	CFO & Executive Director	26.8yrs	sin datos	0.76% THB 236.7m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	sin datos	sin datos
Paramjit Sawhney	President of International	no data	sin datos	1.5% THB 464.5m
Girish Wadhwa	President of Myanmar	no data	sin datos	sin datos
Manoj Gurbuxani	Deputy Chief Financial Officer	4.8yrs	sin datos	0.000010% THB 3.1k
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	sin datos	1.48% THB 457.3m
Sujintana Boonworapat	Corporate Secretary	no data	sin datos	0.019% THB 6.0m

26.8yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MEGA es experimentado (26.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Vivek Dhawan	CEO, Chief Coach & Executive Director	11.8yrs	sin datos	6.59% THB 2.0b
Thomas Abraham	CFO & Executive Director	26.8yrs	sin datos	0.76% THB 236.7m
Yim Chi	Independent Vice Chairma	11.8yrs	฿1.58m	sin datos
Kirit Chimanlal Shah	Non-Executive Director	11.8yrs	฿661.50k	49.81% THB 15.4b
Shiraz Poonevala	Non-Executive Director	11.8yrs	฿661.50k	sin datos
Ishaan Shah	Non-Executive Director	11.8yrs	฿661.50k	0.32% THB 98.9m
Mechai Viravaidya	Independent Chairman	11.8yrs	฿2.21m	sin datos
Sameera Shah	Non-Executive Director	11.8yrs	฿661.50k	sin datos
Thor Santhisiri	Independent Director	11.8yrs	฿1.15m	0.022% THB 6.7m
Vijay Karwal	Independent Director	3.5yrs	฿1.15m	sin datos
Nithinart Sinthudeacha	Independent Director	1.8yrs	฿1.15m	sin datos

11.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de MEGA son experimentados ( 11.8 años antigüedad media).

Mega Lifesciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad